Stamulumab

Stamulumab

Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	myostatin
Clinical data
Routes of administration	injection only
Identifiers
CAS Number	705287-60-1
ATC code	none
Chemical data
Formula	C6330H9748N1672O1668S48
Molar mass	137.5 kDa[[]]

Stamulumab (MYO-029) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab was formulated and tested by Wyeth in Collegeville, Pennsylvania. Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.

Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for Duchenne muscular dystrophy

Phase 1 and 2 trials

Wyeth undertook a Phase 1 and 2 clinical trial in 2005 and 2006 of stamulumab. The multiple ascending dose trial (36 patients per cohort) contained some measures of efficacy. The trial's participants included people afflicted with Facioscapulohumeral muscular dystrophy, Becker's muscular dystrophy, and Limb-girdle muscular dystrophy. Through 2007 Wyeth has been analyzing the results but the hoped-for news and/or a publication in 2007 did not occur. However, as of January 24, 2008, the study has been accepted by a peer-reviewed journal and publication is expected "in the next few months" On 11 March 2008 it was announced that Wyeth would not develop the drug further for MD, but would continue to explore myostatin inhibition along with other strategies.

See also

• ACVR2B is similar to stamulumab but is not an antibody; rather, it provides a portion of the molecule to which myostatin would normally bind thus preventing the myostatin from binding with the actual molecule.